Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes

Journal of Pharmacology and Experimental Therapeutics

Volumn 292, Issue 3, 2000, Pages 1071-1079

  Dams, Els T M ^a   Laverman, Peter ^a   Oyen, Wim J G ^a   Storm, Gert ^b   Scherphof, Gerrit L ^c   Van Der Meer, Jos W M ^a   Corstens, Frans H M ^a   Boerman, Otto C ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOSOME;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG TARGETING; DRUG TRANSPORT; DRUG UPTAKE; MOUSE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; RAT;

ANIMALS; COMPLEMENT SYSTEM PROTEINS; DRUG CARRIERS; FEMALE; INJECTIONS; LIPOSOMES; LIVER; MACACA MULATTA; MALE; METABOLIC CLEARANCE RATE; MICE; POLYETHYLENE GLYCOLS; RATS; RATS, WISTAR; SPECIES SPECIFICITY; TISSUE DISTRIBUTION;

EID: 0034054078     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Abrams MJ, Juweid M, ten Kate CI, Schwartz DA, Hauser MM., Gaul FE, Fuccello AJ, Rubin RH, Strauss HW and Fischman AJ (1990) Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med 31:2022-2028.
2. Alving CR (1984) Natural antibodies against phospholipids and liposomes in humans. Biochem Soc Trans 12:342-344.
3. Baker HJ, Lindsey JR and Weisbroth SH (1979) Selected normative data. Appendix I, in The Laboratory Rat (Baker HJ, Lindsey JR and Weisbroth SH eds) pp 412-413, Academic Press, New York.
4. Daemen T, Hofstede G, ten Kate MT, Bakker Woudenberg IA and Scherphof GL (1995) Liposomal doxorubicin-induced toxicity: Depletion and impairment of phagocytic activity of liver macrophages. Int J Cancer 61:716-721.
5. Daemen T, Velinova M, Regts J, de Jager M, Kalicharan R, Donga J, van der Want JJ and Scherphof GL (1997) Different intrahepatic distribution of phosphatidylglycerol and phosphatidylserine liposomes in the rat. Hepatology 26:416-423.
6. Devine DV and Marjan JM (1997) The role of immunoproteins in the survival of liposomes in the circulation. Crit Rev Ther Drug Carrier Syst 14:105-131.
7. Fraker PJ and Speck JC Jr (1978) Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun 80:849-857.
8. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, Martin F, Huang A and Barenholz Y (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54:987-992.
9. Gabizon AA (1992) Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res 52:891-896.
10. Goebel FD, Goldstein D, Goos M, Jablonowski H and Stewart JS (1996) Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. The International SL-DOX Study Group. Br J Cancer 73:989-994.
11. Goins B, Philips WT and Klipper R (1998) Repeat injection studies of technetium-99m-labeled PEG-liposomes in the same animal. J Liposome Res 8:265-281.
12. Harashima H, Sakata K, Funato K and Kiwada H (1994) Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes. Pharm Res 11:402-406.
13. Harrison M, Tomlinson D and Stewart S (1995) Liposomal-entrapped doxorubicin: An active agent in AIDS-related Kaposi's sarcoma. J Clin Oncol 13:914-920.
14. Hengge UR, Brockmeyer HN, Raßhofer R. and Goos M (1993) Fatal hepatic failure with liposomal doxorubicin (Letter). Lancet 341:383-384.
15. Hu Q and Liu D (1996) Co-existence of serum-dependent and serum-independent mechanisms for liposome clearance and involvement of non-Kupffer cells in liposome uptake by mouse liver. Biochim Biophys Acta 1284:153-161.
16. Huang SK, Mayhew E, Gilani S, Lasic DD, Martin FJ and Papahadjopoulos D (1992) Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res 52:6774-6781.
17. Johnson MD, Drew RH and Perfect JR (1998) Chest discomfort associated with liposomal amphotericin B: Report of three cases and review of the literature. Pharmacotherapy 18:1053-1061.
18. Kors JW, van Doormaal JJ, Breukelman H, van Voorst Vader PC and De Monchy JG (1996) Long-term follow-up of indolent mastocytosis in adults. J Intern Med 239:157-164
19. Laverman P, Dams ETM, Oyen WJG, Storm G, Koenders EB, Prevost R, van der Meer JWM, Corstens FHM and Boerman OC (1999) A novel method to label liposomes with Tc-99m via the nicotinyl hydrazino derivative. J Nucl Med 40:192-197.
20. Liu D, Hu Q and Song YK (1995a) Liposome clearance from blood: Different animal species have different mechanisms. Biochim Biophys Acta 1240:277-284.
21. Liu D, Liu F and Song YK (1995b) Recognition and clearance of liposomes containing phosphatidylserine are mediated by serum opsonin. Biochim Biophys Acta 1235: 140-146.
22. Liu S, Ishida T and Kiwada H (1998) Characterization of bovine serum factor triggering the lysis of liposomes via complement activation. Biol Pharm Bull 21:390-397.
23. Mayer MM (1971) Complement and complement fixation, in Experimental Immunochemistry (Kabat EA ed) pp 133-240, Thomas, Springfield, IL.
24. Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, Roman L, Uziely B, Muderspach L, Garcia A, Burnett A, Greco FA, Morrow CP, Paradiso LJ and Liang LJ (1997) Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15:987-993.
25. Northfelt DW, Dezube BJ, Thommes JA, Levine R, Von Roenn JH, Dosik GM, Rios A, Krown SE, DuMond C and Mamelok RD (1997) Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J Clin Oncol 15:653-659.
26. Oussoren C and Storm G (1997) Lymphatic uptake and biodistribution of liposomes after subcutaneous injection: III. Influence of surface modification with poly(ethyleneglycol). Pharm Res 14:1479-1484.
27. Oussoren C and Storm G (1999) Effect of repeated intravenous administration on circulation kinetics of poly(ethyleneglycol)-liposomes in rats. J Liposome Res 9:349-355.
28. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, Lee KD, Woodle MC, Lasic DD and Redemann C (1991) Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA. 88:11460-11464.
29. Peters AM and Lewis SM (1995) Haematology, in Clinical Nuclear Medicine (Maisey MN, Britton KE and Gilday DL eds) pp 346-382, Chapman & Hall Medical, London.
30. Rahman A, Treat J, Roh JK, Potkul LA, Alvord WG, Forst D and Woolley PV (1990) A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. J Clin Oncol 8:1093-1100.
31. Scherphof GL, Roerdink F, Dijkstra J, Ellens H, de Zanger R and Wisse E (1983) Uptake of liposomes by rat and mouse hepatocytes and Kupffer cells. Biol Cell 47:47-58.
32. Szebeni J (1998) The interaction of liposomes with the complement system. Crit Rev Ther Drug Carrier Syst 15:57-88.
33. Treat J, Greenspan A, Forst D, Sanchez JA, Ferrans VJ, Potkul LA, Woolley PV and Rahman A (1990) Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: Phase II study. J Natl Cancer Inst 82:1706-1710.
34. Vaage J, Barbera Guillem E, Abra R, Huang A and Working P (1994) Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. Cancer 73:1478-1484.
35. Vail DM, Chun R, Thamm DH, Garrett LD, Cooley AJ and Obradovich JE (1998) Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: A randomized, double-blind clinical trial using a canine model. Clin Cancer Res 4:1567-1571.
36. Wassef NM and Alving CR (1993) Complement-dependent phagocytosis of liposomes. Chem Phys Lipids 64:239-248.
37. Wassef NM, Johnson SH, Graeber GM, Swartz GM Jr, Schultz CL, Hailey JR, Johnson AJ, Taylor DG, Ridgway RL and Alving CR (1989) Anaphylactoid reactions mediated by autoantibodies to cholesterol in miniature pigs. J Immunol 143:2990-2995.
38. Woodle MC and Lasic DD (1992) Sterically stabilized liposomes. Biochim Biophys Acta 1113:171-199.